In hMSC-TERT cells, Fedratinib had no major effects on viability at 0.3 μM and 3 μM, but decreased viability at 30 μM after 3 days. Treatment with Fedratinib at 3 µM for 3 days produced no significant changes in apoptotic cell numbers compared with DMSO-vehicle treated control cells and did not cause cell death. In HEK293T cells, Fedratinib showed concentration-dependent inhibition of SLC19A2- and SLC19A3-mediated [3H] thiamine uptake. In thermal shift assays with recombinantly purified hSLC19A3, Fedratinib showed high-affinity binding with Kd,app = 1.0 ± 0.2 μM. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Fedratinib effects on hMSC-TERT cell viability
Cell-based study · hMSC-TERT [1]
hMSC-TERT cells received continuous Fedratinib exposure. Fedratinib had no major effects on viability at 0.3 μM and 3 μM, but decreased viability at 30 μM after 3 days.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.3, 3, and 30 μM
- Exposure duration
- for 1, 2, and 3 days
- Method
- continuous exposure
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Fedratinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S4, S6, S7); 4. Materials and Methods > 4.3. Cell Viability Assay (S35, S36); Figure 1 legend (S63)
hMSC-TERT cell viability: hMSC-TERT cell viability; comparator: DMSO-vehicle-treated control cells — 2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S4, S6, S7)
Fedratinib inhibition of transporter-mediated thiamine uptake
Cell-based study · HEK293T cells [2]
In HEK293T cells, Fedratinib showed concentration-dependent inhibition of SLC19A2- and SLC19A3-mediated [3H] thiamine uptake.
Literature-Reported Treatment Conditions
- Exposure duration
- 3 min
- Vehicle
- HBSS buffer
- Reported limits
- Not stated in the sentences used: dose, route, control.
Methods and source locations
Compound reported in the paper: Fedratinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Inhibition of SLC19A3 by antineoplastic fedratinib (S70); Methods > [3H]-Thiamine cellular uptake assay (S206, S207); Fig. 4 legend (S267)
SLC19A2- and SLC19A3-mediated [3H] thiamine uptake: SLC19A2- and SLC19A3-mediated [3H] thiamine uptake — Fig. 4 legend (S267)
Fedratinib binding to purified thiamine transporter
Biochemical assay · recombinantly purified hSLC19A3 [3]
Recombinantly purified hSLC19A3 was exposed to Fedratinib in thermal shift assays. Fedratinib showed high-affinity binding, with Kd,app = 1.0 ± 0.2 μM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 μM to 2 mM
- Exposure duration
- 30 min at room temperature
- Method
- supplied with the respective compounds
- Vehicle
- SEC buffer
Methods and source locations
Compound reported in the paper: Fedratinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Drug interactions of SLC19A3 (S134, S153); Methods > Thermal stability measurements and binding affinity determination (S218, S219, S224, S225)
apparent binding affinities at 25 °C: apparent binding affinities at 25 °C; comparator: the apo state (Tmapo) — Results > Drug interactions of SLC19A3 (S153); Methods > Thermal stability measurements and binding affinity determination (S225)
Fedratinib effects on apoptosis in hMSC-TERT cells
Cell-based study · hMSC-TERT cells [1]
hMSC-TERT cells were treated with Fedratinib at 3 µM for 3 days. No significant changes in apoptotic cell numbers were observed compared with DMSO-vehicle treated control cells, and this concentration did not cause cell death.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3 µM
- Exposure duration
- for 3 days
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Fedratinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S8); 4. Materials and Methods > 4.4. Measurement of Apoptosis (S39, S40); Figure 1 legend (S62, S64)
number of apoptotic cells: number of apoptotic cells; comparator: DMSO-vehicle treated control cells — 2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S8)